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Abstract
An association between exposure to a risk factor and age-at-onset of disease may reflect an effect
on the rate of disease occurrence or an acceleration of the disease process. The difference in age-
at-onset arising from case-only studies, however, may also reflect secular trends in the prevalence
of exposure to the risk factor. Comparisons of age-at-onset associated with risk factors are
commonly performed in case series enrolled for genetic linkage analysis of late onset diseases. We
describe how the results of age-at-onset studies of environmental risk factors reflect the underlying
structure of the source population, rather than an association with age-at-onset, by contrasting the
effects of coffee drinking and cigarette smoking on Parkinson disease age-at-onset with the effects
on age-at-enrollment in a population based study sample. Despite earlier evidence to suggest a
protective association of coffee drinking and cigarette smoking with Parkinson disease risk, the age-
at-onset results are comparable to the patterns observed in the population sample, and thus a
causal inference from the age-at-onset effect may not be justified. Protective effects of multivitamin
use on PD age-at-onset are also shown to be subject to a bias from the relationship between age
and multivitamin initiation. Case-only studies of age-at-onset must be performed with an
appreciation for the association between risk factors and age and ageing in the source population.
Background
Studies of the relation between a risk factor and age-at-
onset of a disease, as opposed to the relation between a
risk factor and the occurrence of disease, are designed to
investigate the hypothesis that the risk factor causes the
disease to occur earlier than it would have occurred with-
out exposure to the risk factor. For example, the risk factor
may accelerate the disease process, so that the average dis-
ease-free survival time from birth to disease onset is
shorter for those exposed to the risk factor than for those
without exposure to the risk factor. Conventional epide-
miologic designs can investigate these hypotheses, but
when only cases are available, age-at-onset studies are a
convenient way to investigate associations between risk
factors and disease. The limitation of the case-only design
is that the analysis cannot account for potential age differ-
ences between those exposed and unexposed to the risk
factor, which would suggest a difference in the onset of
exposed and unexposed cases, but without any etiologic
relevance.
Though many epidemiologists appreciate this inherent
shortcoming of using age-at-onset of disease as an out-
come, it has become an increasingly common outcome
measure in genetic epidemiology studies of late onset dis-
eases such as Parkinson and Alzheimer disease [1,2].
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a disease often enroll only cases, so these case-only studies
can investigate the association between risk factors and
age-at-onset, but not the association between risk factors
and the occurrence of disease itself. While such studies of
age-at-onset may be appealing, since identifying factors
related to delayed onset might facilitate the development
of therapeutic agents or public health interventions, a
study associating age-at-onset with a risk factor that may
vary over time is susceptible to confounding by age itself.
Age may not only be related to age-at-onset but also be
related to the prevalence of exposure to the risk factor.
Since only cases appear in the analysis, an underlying
association between the risk factor and age in the source
population that gave rise to the cases can be too easily
ignored [3], and a difference in age-at-onset of disease
could be interpreted to have etiologic importance.
The comparison of age-at-death for left-handers with age-
at-death for right-handers provides a classic illustration
[4,5]. The authors observed a 9 year earlier age-at-death
for left-handers [5], and speculated that it may have arisen
from prenatal or perinatal birth stressors, genetic effects
and intrauterine hormones that reduced immune func-
tion, or accidents in an environment designed for a right-
handed majority [4]. They even noted that deaths by acci-
dents were more common among left-handers than right-
handers. In reality, many left-handers born in the early
part of the twentieth century were forced to use their right
hand, a practice that has disappeared over time. Those
born later in the century were less likely to be forced to use
their right hand. In these studies conducted toward the
end of the twentieth century, persons dying at old age
were less likely to be classified as left-handed because of a
birth cohort effect [6]. Those dying at young ages, but at
the same calendar time, were not as likely to have suffered
this social pressure, so were correctly classified as left
handed. Deaths due to accidents were more common
among left-handers because left-handers were younger
and deaths among young people are more likely acciden-
tal. Birth cohort effects best explain the difference in age-
at-death, which could have been revealed had denomina-
tor data, such as mortality rates, been available. Subse-
quent prospective cohort studies have shown that left-
handers and right-handers have equivalent mortality rates
[7-9]. These studies of age-at-death were difficult to inter-
pret because secular trends influenced the prevalence of
left-handedness, which resulted in an underlying associa-
tion between left-handedness and age in the source popu-
lation. We illustrate similar concerns about studying age-
at-onset in case-only studies and provide a cautionary tale
from a research study of age-at-onset of Parkinson's Dis-
ease.
Parkinson's disease (PD [MIM 168600]) is a neurodegen-
erative disease with onset in mid to late life, and it is usu-
ally characterized by tremor, rigidity, bradykinesia, and
therapeutic response to levodopa. PD is caused by the
slow degeneration of dopamine-producing neurons in the
substantia nigra, but the etiology of this degeneration is
not well understood [10]. To date, several genome wide
scans for PD have been performed and multiple chromo-
somal regions have been implicated in PD etiology [11-
13], though the population attributable fraction for each
individual gene or region appears to be low. Epidemio-
logic studies of non-genetic factors have suggested that a
history of head trauma may increase PD risk [14], while
coffee drinking and cigarette smoking may decrease PD
risk. In a meta-analysis, Hernan and colleagues reported a
relative risk (RR) for PD of 0.69 [95% confidence interval
(CI) 0.59–0.80) in coffee drinkers compared with non-
coffee drinkers and a RR of 0.59 (95% CI 0.54–0.63) for
ever smokers compared to never smokers [15].
The observation of decreased risk for PD in coffee drinkers
and cigarette smokers fostered the hypothesis that sub-
stances in coffee and cigarettes, namely caffeine and nico-
tine, protect against the neurodegenerative mechanisms
that ultimately lead to PD. The potential neuroprotective
effect of caffeine is supported by findings from mouse
models of PD, in which a low dose of caffeine before
administration of the neurotoxin MPTP attenuated
dopamine depletion [16]. Similar neuroprotective effects
for nicotine have been observed in animal models [17].
A recent report extended the hypothesis that smoking pro-
tects against PD occurrence to the hypothesis that smok-
ing delays onset among cases [18]. They compared
average age-at-onset in ever-smokers with never-smokers,
finding that onset age was significantly older among ever-
smokers compared to never-smokers (a difference in
onset symptoms of 3.5 years with 95% CI from 1.6 to
5.4), and argued that a bias explaining these results was
unlikely. Our studies suggest that the validity of this infer-
ence, on the basis of an association between smoking and
age-at-onset in a case-only design, is questionable. In this
report, we used data from the GenePD study to evaluate
whether the associations between coffee drinking and cig-
arette smoking and age-at-onset of PD reflected secular
trends in the prevalence of exposure to these risk factors.
We re-evaluated the prior reports of an association
between head trauma and multivitamin use with age-at-
onset in this sample. Previous reports have reviewed the
pitfalls of case-only designs to assess gene-environment
interactions [19,20]; we focus on the subset of case-only
analyses that assess age-at-onset, some of which make use
of study populations originally enrolled to investigate
genetic hypotheses.Page 2 of 6
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The GenePD study is a multi-center study of affected rela-
tive pairs with PD that was designed for genetic linkage
analyses [11,21]. Recruitment began in 1997 and is ongo-
ing. Participants in the current analysis were born between
1901 and 1963 and diagnosed with PD between 1965 and
2002. Recruitment included both prevalent and incident
cases, with a median difference between age-at-onset and
enrollment of 7.5 years (range: 0 to 40 years). Risk factor
data on history of head trauma and consumption of cof-
fee, cigarettes, and multivitamins were collected by ques-
tionnaire and specifically inquired about the year(s) of
exposure. Participants were classified as exposed to a risk
factor only when exposure occurred before the age-at-
onset. The case-only design of this familial study lends
itself to studies that relate age-at-onset of PD to risk factor
exposures. The GenePD study previously reported an asso-
ciation between a history of head trauma and younger age
of PD onset, and associations between the use of multivi-
tamins and greater pack-years of smoking with older age-
at-onset [21]. At the time of this earlier publication, coffee
drinking was not strongly associated with age-at-onset of
PD. As recruitment has continued, these associations have
continued to be evaluated in the growing sample.
The findings previously reported for multivitamin use and
pack-years of smoking associated with later age-at-onset
of PD are examples of the difficulty of studying associa-
tions between non-genetic risk factors and age-at-onset.
While the number of pack-years is a commonly used
measure of smoking dose and duration, its use to evaluate
an association between smoking and onset age is inher-
ently biased by the role of age in both the dependent and
independent variable. The finding of later age-at-onset
with larger number of pack-years of smoking reflects that
older smokers have smoked for a longer time than
younger smokers and also is likely to reflect a birth cohort
effect influencing the age of smoking initiation. The find-
ing should not be interpreted as suggesting that smoking
delays the onset of PD, the protective association reported
in the meta-analysis notwithstanding [15]. Although it is
plausible that smoking both reduces the risk of PD occur-
rence and delays its onset, the association between pack-
years of smoking and age-at-onset of PD should not be
relied upon to reach either conclusion.
The reported association between multivitamin use and
older age-at-onset was similarly plagued by the associa-
tion between multivitamin use and age in the source pop-
ulation. We evaluated the association between
multivitamin use and PD age-at-onset by calculating the
average age-at-onset of PD in a reference group of never-
users of multivitamins and comparing it with the average
age-at-onset in multivitamin users in which we sequen-
tially incorporated cases who began using multivitamins
at ever increasing ages. We observed that the association
of a later age of PD onset with multivitamin use appeared
only when we included users who initiated multivitamin
use at age 70 years or older. In fact, restricting the users to
those who initiated multivitamin use at the youngest ages
showed an association with earlier onset age. This differ-
ence likely reflects a birth cohort effect because younger
cases, born in more recent health conscious years, were
more likely to use multivitamins before onset of PD com-
pared to the group of cases who were never users of mul-
tivitamins. Table 1 reports the estimates of the mean
differences in age-at-onset and their 95% confidence
intervals from a linear regression model relating multivi-
tamin use to PD age-at-onset across the initiation age cut-
offs. The inconsistency in the direction and magnitude of
the difference across exposure age cutoffs does not suggest
a true effect. If multivitamin use was truly protective, we
would expect consistency in the direction of the effect
across exposure age cut-offs, as is the case in the head
trauma example below. Rather, it suggests that the origi-
nal finding with a dichotomous multivitamin use variable
was biased by the ever-increasing proportion of the source
population taking vitamins as they age.
Table 1: The association of multivitamin use and head trauma with PD age-at-onset.
Multivitamin use Head trauma
Exposure Age N exposed Difference in
age-at-onset (years)
95% CI N exposed Difference in
age-at-onset (years)
95% CI
≤30 62 -2.0 -5.2, 1.2 67 -4.9 -7.7, -2.0
≤40 92 -1.9 -4.5, 0.8 73 -5.1 -7.8, -2.5
≤50 128 0.3 -2.1, 2.7 79 -4.8 -7.3, -2.3
≤60 163 1.2 -0.9, 3.3 88 -4.2 -6.6, -1.9
≤70 187 2.6 0.6, 4.6 90 -4.0 -6.4, -1.6
≤80 194 3.1 1.1, 5.2 91 -3.8 -6.2, -1.5
Analysis performed by sequentially increasing the upper age limit for exposure, but maintaining a constant reference group of never-users of 
multivitamins (N = 342; mean age-at-onset 60.6 years) or no history of head trauma (N = 451; mean age-at-onset 62.4 years). Negative β estimates 
reflect a younger mean age-at-onset in the exposed group.Page 3 of 6
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present a parallel analysis of the relation between head
trauma and PD onset age (Table 1). A history of head
trauma was present when participants reported a head
injury severe enough to cause a loss of consciousness,
blurred/double vision, dizziness, vertigo, seizures, con-
vulsions, temporary memory loss, or paralysis. The
reported association between a history of head trauma
and younger age-at-onset of PD appears to be robust to
the bias observed in the analysis of multivitamin use. The
finding is plausible because of the established association
between head trauma and increased risk of PD, but the
result associating head trauma with younger onset of PD
may still be plagued by the biases of studying age-at-onset
in prevalent cases and the potential for differential recall
bias due to age-related memory loss or survival with PD.
Given that the protective associations between coffee
drinking and cigarette smoking and risk of PD have been
replicated in many studies and in animal models, we have
continued to investigate the association between these
factors and age-at-onset of PD. To further evaluate our
findings of an association between coffee drinking, smok-
ing, and PD age-at-onset, we compared them to the asso-
ciations between coffee drinking, smoking, and age-at-
enrollment in the unselected sample of the population-
based National Heart, Lung, and Blood Institute (NHLBI)
Family Heart Study (FHS). FHS participants were recruited
from existing family-based epidemiologic studies by one
of two recruitment mechanisms 1) a random selection of
2000 participants yielding 588 families with complete
clinic exams, or 2) a selection of 2000 participants with a
reported family history of coronary heart disease yielding
657 families with clinic exams [22]. For comparison with
the PD sample, only members of families recruited
through random selection were studied.
We investigated the age-at-event associations in the
GenePD Study and FHS in parallel. Enrollment in FHS
serves as a proxy event to compare to age-at-onset that is
not expected to be associated with any exposure in a pop-
ulation sample. Since both are family designs, we used a
generalized estimating equation to calculate the standard
error of the beta estimates, which accounts for the multi-
ple observations within a family. Age-at-onset of PD and
age-at-enrollment in FHS were used as the quantitative
dependent variables and independent variables for coffee
drinking (yes/no), former smoking (yes/no), and current
smoking (yes/no) at the time of PD onset or FHS enroll-
ment were included in the model. For the study in
GenePD, the head trauma covariate (yes/no) was also
included. For comparability, we restricted FHS subjects to
those enrolled within the age range of PD subjects' ages-
at-onset (20–88 years). The analyses were repeated
restricting the individuals to age-at-onset or enrollment of
at least 45 years. Results are reported in Table 2. Coffee
drinking and current cigarette smoking are predictors of
PD age-at-onset and age at-enrollment in both the full and
age-restricted samples. The direction and estimate of the
effect size between the GenePD Study and the FHS sample
are comparable, with substantially overlapping 95% con-
fidence intervals.
Conclusion
The results presented here cast considerable doubt that a
valid relation exists between multivitamin use, coffee
drinking, or cigarette smoking and age-at-onset of PD. If
multivitamin use truly delayed the onset of PD, we would
expect to observe the largest difference in age-at-onset
among the group that initiated their multivitamin use at
the youngest ages, but this pattern was not observed. For
coffee drinking, it is tempting to see the results within the
GenePD study in conjunction with prior studies of coffee
and PD risk and speculate that coffee has potential neuro-
protective effects that delay onset of PD. However, the
comparison of the GenePD association with the FHS asso-
ciation suggests that the finding is related to a secular
trend in coffee consumption, with older individuals being
more likely to self identify as regular coffee drinkers than
younger individuals. The result for current smoking does
Table 2: The association of coffee drinking and cigarette smoking with PD age-at-onset and with FHS age-at-enrollment.
GenePD – difference in age-at-onset of PD (years) FHS – difference in age-at-enrollment (years)
β estimate* 95%CI β estimate* 95%CI
All subjects N = 542 N = 2017
Coffee drinking 4.0 1.3, 6.7 3.0 1.6, 4.5
Former smoking 0.7 -1.3, 2.6 3.1 1.6, 4.6
Current smoking -6.4 -9.9, -2.9 -5.0 -7.2, -2.9
Subjects ≥ 45 yrs N = 496 N = 1380
Coffee drinking 2.1 0.0, 4.1 1.3 0.3, 2.4
Former smoking 0.6 -1.1, 2.2 0.3 -0.7, 1.3
Current smoking -4.2 -7.4, -1.1 -2.9 -4.5, -1.3
*Positive β estimates reflect an older mean age-at-onset (or enrollment) in the exposed group.Page 4 of 6
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risk, but exemplifies a population trend for smoking ces-
sation at older ages. These findings for PD age-at-onset
should not be interpreted as a refutation of prior findings
associating these exposures with PD risk.
One might ask whether it is ever possible to perform an
unbiased study of the association between risk factors and
age-at-onset? We believe that the answer is yes, but that it
requires thoughtful study design and knowledge about
how the risk factors are related to age and ageing in the
source population [23]. It is unlikely that we can validly
study risk factors that are inherently related to age as sim-
ple categorical indicators. The example of multivitamin
use and PD age-at-onset demonstrates this difficulty, in
which a protective association was reported based on a
small number of relatively older onset PD individuals
who initiated multivitamin use just before diagnosis, but
not necessarily at a time with a relevant induction period.
Their initiation of multivitamin use may have been
related to self-medication of preclinical symptoms of PD.
Valid studies of age-at-onset require no underlying associ-
ation between the risk factor and aging or birth cohort in
the source population. They must also consider whether a
sufficient induction time has passed for the risk factor to
have an effect. When these criteria and others [23] cannot
be satisfied, age-specific or standardized risks or rates, or a
population-based case-control design, must be used to
study the association between the risk factor and out-
come. These designs allow the investigator to disaggregate
the relation between aging and the prevalence of the risk
factor, using familiar methods to control confounding in
the design or analysis. When prior knowledge strongly
suggests that the prevalence of the risk factor changes with
age in the source population, case-only studies may sup-
port a relation between the risk factor and age-at-onset,
regardless of whether the inference is justified.
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